Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Haggenburg, SabineHofsink, Quincy
Lissenberg-Witte, Birgit I
Broers, Annoek E C
van Doesum, Jaap A
van Binnendijk, Rob S
den Hartog, Gerco
Bhoekhan, Michel S
Haverkate, Nienke J E
Burger, Judith A
Bouhuijs, Joey H
Smits, Gaby P
Wouters, Dorine
van Leeuwen, Ester M M
Bontkes, Hetty J
Kootstra, Neeltje A
Zweegman, Sonja
Kater, Arnon P
Heemskerk, Mirjam H M
Groen, Kaz
van Meerten, Tom
Mutsaers, Pim G N J
Beaumont, Tim
van Gils, Marit J
Goorhuis, Abraham
Rutten, Caroline E
Hazenberg, Mette D
Nijhof, Inger S
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.Published in
JAMA oncology 2022; 8(10):1477-1483PMID
35951338ae974a485f413a2113503eed53cd6c53
10.1001/jamaoncol.2022.3227
Scopus Count
Collections